Table 2.
Dendritic cell membrane coated drug-loaded nanoparticles targeted cancer therapy
| Type of membrane | Core nanoparticles | Cargo | Combined treatment | Types of cancer | in vitro model | Mechanisms and functions | Ref. |
|---|---|---|---|---|---|---|---|
| DCm | PLGA | IL-2 | immunotherapy | Ovarian cancer | ID8 |
1. The activation of T cells is triggered by antigen presentation 2. The nano-size effect helps break through the time and space limitations in the antigen presentation process 3. The inhibition effect of tumor growth delay and metastasis was significantly improved |
[32] |
| DCm | Poly (disulfide ester amide) (PDEA) polymers | Hydrophobic oxaliplatin (OXA) prodrugs | Chemotherapy | Colon cancer | CT26 |
1. The T cell response is initiated through antigen presentation 2. Immature dendritic cells are activated 3. NPs induce immunogenic cell death, and the mitochondrial pathway induces tumor cell death, thereby creating an immunogenic microenvironment 4. The effector factors of the immune system effectively inhibit the growth and metastasis of distal tumors |
[[168]] |
| DCm | \ | Photosensitizers (AIE) | Photodynamic therapy | Breast cancer | 4T1 |
1. T cell proliferation is activated by antigen presentation 2. The AIE photosensitizer can effectively accumulate around the tumor through crossing the biological barrier and hitchhiking |
[[176]] |
| DCm | Poly (lactic-co-glycolic acid) (PLGA) | Rapamycin (RAPA) | Chemotherapy | Glioma | C6, 4T1 |
1. T cells are recognized and activated directly or indirectly 2. Homotypic targeting is enhanced through the blood–brain barrier 3. Long-term immunotherapy is provided 4. The secretion of immunostimulatory cytokines relieves the immunosuppressive tumor microenvironment |
[[163]] |
| DCm | Distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy [polyethylene glycol]-2000) (DSPE-PEG) | Photothermal agents (IR-797) | Photothermal therapy | Breast cancer | 4T1 |
1. T cells are activated in situ or in lymph nodes to secrete cytokines 2. The expression of heat shock protein in tumor cells is decreased, while heat stress is increased 3. Laser irradiation is used for photothermal therapy 4. Immunogenic cell death is induced |
[[164]] |
| DCm | Cancer cell membrane-coated PLGA nanoparticles | Anti-programmed death-1 antibodies | Immunotherapy | Melanoma | B16-OVA |
1. T cells are directly cross-initiated to stimulate a strong, antigen-specific anti-tumor response 2. Cooperation is established with the clinical anti-programmed death-1 antibody |
[[167]] |
| DCm |
Histidine-modified stearic acid-grafted chitosan (HCtSA), and DCm/HCtSA/ ovalbumin (OVA) micelles |
\ | \ | Melanoma | B16-OVA |
1. Targeting lymph nodes induces cellular immunity 2. Antigen release behaves in a pH-dependent manner |
[[173]] |
| Hybrid membrane based on C6 cell membranes and DC membranes | Surfactant SDC | Docetaxel (DTX) | Chemotherapy | Glioma | C6 |
1. Drugs are delivered through homologous targeted precise delivery 2. Antigen presentation and immune activation of the downstream immune system occur |
[[51]] |
| Hybrid membrane based on 4T1 cells membranes and DC membranes | Porphyrin-based Zr-MOF (PCN-224) | Nanophotosensitizers | Photodynamic therapy | Breast cancer | 4T1 |
1. Tumors exhibit self-targeting characteristics 2. A photosensitizer is coated for synergistic photodynamic therapy (PDT) 3. The PDT of the primary tumor enhances the regression of a non-radiation distant tumor, caused by immunotherapy |
[[166]] |
| Hybrid membrane based on murine colon adenocarcinoma MC38 cells membranes and DC membranes | PLGA | CpG ODN | Immunotherapy | Colon cancer, brain cancer | MC38 |
1. T cells are activated upon penetration of immune organs 2. An immune adjuvant is co-delivered |
[[28]] |
| Hybrid membrane based on OC cells membranes and DC membranes | Poly (lactic-co-glycolic acid) (PLGA) | Immune adjuvant CpG-oligodeoxynucleotide (CpG-ODN) | Immunotherapy | Ovarian cancer | ID8 |
1. T cells are activated both directly and indirectly 2. An immune adjuvant acts synergistically |
[[172]] |
| Hybrid membrane based on 4T1 cells membranes and DC membranes | Silica nanoparticle | R837 Immune adjuvant | Immune checkpoint blockade | Breast cancer | 4T1 |
1. Tumor growth is inhibited by combined immune checkpoint blockade 2. The immunosuppressive microenvironment and immune memory effect are regulated 3. Antigen delivery and homogeneous targeting are achieved |
[[225]] |
| Hybrid membrane based on 4T1 cells membranes and DC membranes | Tetrakis (4- carboxyphenyl) porphyrin (TCPP) | \ | \ | Breast cancer | 4T1 |
1. Lymph node homing is facilitated 2. T cells are activated by antigens |
[[165]] |